Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques

AIDS

Volumn 14, Issue 16, 2000, Pages 2445-2455

  Patterson, L Jean ^a   Peng, Bo ^a   Abimiku, Alash'le G ^b   Aldrich, Kristine ^a   Murty, Lalita ^a   Markham, Phillip D ^c   Kalyanaraman, V S ^c   Alvord, W Gregory ^d   Tartaglia, James ^e   Franchini, Genoveffa ^a   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Virogenetics Corporation   (United States)

Author keywords

AIDS vaccine; Cross protection; HIV 1; HIV 2; Poxvirus; Rhesus macaques; SHIV

Indexed keywords

CD8 ANTIGEN; CROSS REACTING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DESIGN; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MALE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROVOCATION TEST; RHESUS MONKEY; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS LOAD;

AIDS VACCINES; ANIMALS; CROSS REACTIONS; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HIV-2; IMMUNIZATION; MACACA MULATTA; MALE; POXVIRIDAE; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033749354     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200011100-00005     Document Type: Article

References (42)

1. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes
2. HIV-I subtypes: Implications for epidemiology, pathogenicity, vaccines and diagnostics
3. Identification of a new human immunodeficiency virus type I distinct from group M and group O
4. Natural protection against HIV-1 infection provided by HIV-2
5. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: No protection of HIV-2 against HIV-1 infection
6. Lack of protection against HIV-1 infection among women with HIV-2 infection
7. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission
8. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine
9. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: A new approach to gene therapy of HIV-infection
10. Molecular inhibition of HIV type 1 by HIV type 2: Effectiveness in peripheral blood mononuclear cells
11. Envelope crossreactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: Correlation between cross-neutralization and reactivity against the main neutralizing site
12. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates
13. An HIV-1 and HIV-2 crossreactive cytotoxic T-cell epitope
14. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
15. Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades
16. Distinct recognition of nonclade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa
17. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients
18. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
19. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais
20. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques
21. NYVAC: A highly attenuated strain of vaccinia virus
22. Vaccinia virus as an expression vector
23. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen
24. Utility of SHIV for testing HIV-1 vaccine candidates in macaques
25. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canary pox (ALVAC) vaccine candidate in cynomolgus monkeys
26. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques
27. Multiple immunizations with attenuated poxvirus HIV-2 recombinants and subunit boosts required for protection of rhesus macaques
28. Host immune response: Neutralizing antibodies
29. Human immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys
30. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: Analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses
31. Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia virus
32. Synthesis, oligomerization, and biological activity of the human immuno-deficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus
33. Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques
34. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal imune responses in rhesus macaques and decreases viral burden following vaginal challenge
35. CD28 costimulation increases CD8+ cell suppression of HIV replication
36. CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: Potential role in vaccine efficacy
37. Characterization of a monoclonal antibody (6G12) recognizing the cynomologus monkey CD3 antigen
38. Genes regulating HLA class 1 antigen expression in T-B lymphoblast hybrids
39. NASBA technology: Isothermal RNA amplification in qualitative and quantitative diagnostics
40. Protective mucosal immunity elicited by targeted lilac lymph node immunization with a subunit SIV envelope and core vaccine in macaques
41. Generation of CD8 suppressor factor and beta chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques
42. Persistent infection of macaques with simian-human immunodeficiency viruses